TEDA BIOMEDICAL (08189) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 226 million, representing a year-on-year increase of 7.01%. Shareholders' attributable loss amounted to RMB 6.43 million, widening by 55.86% compared to the same period last year. Loss per share was 0.317 cents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.